References
- International Diabetes Federation. Diabetes Atlas, 2007; IDF, Brussels, Belgium
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
- Ling T. Assessing the impact of complications on the costs of type 2 diabetes in urban China. Chinese J. Diabetes 2003;11:238-241
- Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002;45:S23-8
- Lopez S.G, Tambascia M, Rosas G.J, et al. Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America. Rev Panam Salud Publica 2007;22:12-20
- Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. J Am Med Assoc 2004;291:335-42
- Harris SB, Ekoe JM, Zdanowicz Y, et al. Glycemic control and morbidity in the Canadian primary care setting. Diabetes Res Clin Pract 2005;70:90-7
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
- Del Prato S, Felton A-M, Munro N, et al. Improving glucose management: ten steps to get more patients with type 2 diabetes to goal. Recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract 2005;59:1345-55
- Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
- Elte JW, Blickle JF. Thiazolidinediones for the treatment of type 2 diabetes. Eur J Intern Med 2007;18:18-25
- Kahn SE, Haffner S, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
- Home PD, Pocok SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD). Lancet 2009;373:2125-35
- Kim YM, Cha BS, Kim DJ, et al. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. Diabetes Res Clin Pract 2005;67:43-52
- Zhu XX. The safety and efficacy of rosiglitazone maleate in the treatment of patients with type 2 diabetes mellitus in China. Zhonghua Nei Ke Za Zhi 2003;42:636-9
- Davidson J, McMorn SO, Waterhouse BR, et al. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Clin Ther 2007;29:1900-14
- Chu KM, Hu OY, Pao LH, et al. Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and Mainland Chinese subjects. J Pharm Pharm Sci 2007;10:411-19
- GlaxoSmithKline AVANDIA US prescribing information. Available from http://us.gsk.com/products/assets/us_avandia.pdf. Accessed 26 October2009
- Takeda Chemical Industries Ltd Actos receives CPMP's recommendation for monotherapy for defined patients with type 2 diabetes. Available from http://www.takeda.com/press/article_760.html. Accessed 26 October 2008
- Majima T, Komatsu Y, Doi K, et al. Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus. Endocr J 2006;53:325-30
- Teramoto T, Yamada N, Shirai K, et al. Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus. J Atheroscler Thromb 2007;14:86-93